Gyre Therapeutics, Inc.

NCM: GYRE

Live Quote

📈 ZcoreAI Score

Our AI model analyzes Gyre Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get GYRE Z-Score →

About Gyre Therapeutics, Inc.

Healthcare Biotechnology

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

📊 Fundamental Analysis

Gyre Therapeutics, Inc. demonstrates a profit margin of 4.3%, which is below the sector average, suggesting competitive pressure.

The company recently reported 33.4% revenue growth, which is well above average for the Healthcare sector.

Return on Equity (ROE) is 8.2%, which suggests room for improvement in capital utilization.

At a current price of $7.39, GYRE currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $6.57 - $11.78).

💰 Valuation Insight

GYRE trades at a 1378.0% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

🔴 Profit Margin Weak

🔴 Debt/Equity Elevated

✅ Revenue Growth Excellent

🔴 Return on Equity Weak

🔴 Beta (Risk) High Volatility

Key Financials

Market Cap

$711.90M

Trailing P/E

369.50

Forward P/E

123.17

Beta (5Y)

6.40

52W High

$11.78

52W Low

$6.57

Avg Volume

98K

Day High

Day Low

Get GYRE Z-Score on Dashboard 🚀